lung cancer phenotype

Aliases

LC, human lung cancer, lung cancer, lung cancer risk, lung carcinoma

Related entities (1)

Mentioned in (137)

Papers in which this entity is mentioned.

• Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types. (2026)
• Integrated in vivo combinatorial functional genomics and spatial transcriptomics of tumours to decode genotype-to-phenotype relationships. (2026)
• Whole-genome landscapes of 1,364 breast cancers. (2026)
• Nanopore-based cell-free DNA fragmentation and methylation profiles from the cerebral spinal fluid of patients with lung cancer brain metastases. (2025)
• Meta-analysis reveals differences in somatic alterations by genetic ancestry across common cancers. (2025)
• Tumour-wide RNA splicing aberrations generate actionable public neoantigens. (2025)
• Rapid brain tumor classification from sparse epigenomic data. (2025)
• Chromosomal instability as a driver of cancer progression. (2025)
• Functional analysis of cancer-associated germline risk variants. (2025)
• Tracing the evolution of single-cell 3D genomes in Kras-driven cancers. (2025)
• OXSeg: Multidimensional Attention UNet-Based Lip Segmentation Using Semi-Supervised Lip Contours. (2025)
• Transcription start sites experience a high influx of heritable variants fueled by early development. (2025)
• Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma. (2024)
• Principles and methods for transferring polygenic risk scores across global populations. (2024)
• Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme. (2024)
• Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology. (2024)
• The Application of Long-Read Sequencing to Cancer. (2024)
• A New Era of Data-Driven Cancer Research and Care: Opportunities and Challenges. (2024)
• ENPP1 Immunobiology as a Therapeutic Target. (2023)
• Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma. (2023)
• A Novel Tissue-Free Method to Estimate Tumor-Derived Cell-Free DNA Quantity Using Tumor Methylation Patterns. (2023)
• Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types from 10,983 cancer patients (2023)
• Predicting tumour content of liquid biopsies from cell-free DNA. (2023)
• Heritable defects in telomere and mitotic function selectively predispose to sarcomas. (2023)
• Cell-Free DNA Fragmentomics: The Novel Promising Biomarker. (2023)
• Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. (2023)
• Towards understandings of serine/arginine-rich splicing factors. (2023)
• RNA splicing dysregulation and the hallmarks of cancer. (2023)
• Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA. (2022)
• At the dawn: cell-free DNA fragmentomics and gene regulation. (2022)
• Single-cell analysis of somatic mutations in human bronchial epithelial cells in relation to aging and smoking. (2022)
• Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. (2022)
• Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing. (2022)
• Inferring gene expression from cell-free DNA fragmentation profiles. (2022)
• Construction and validation of a novel gene signature for predicting the prognosis of osteosarcoma. (2022)
• Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. (2021)
• Nanopore sequencing technology, bioinformatics and applications. (2021)
• Application of third-generation sequencing in cancer research. (2021)
• Alternative splicing: Human disease and quantitative analysis from high-throughput sequencing. (2021)
• Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. (2021)
• Multivariate analysis of 1.5 million people identifies genetic associations with traits related to self-regulation and addiction. (2021)
• Detection and characterization of lung cancer using cell-free DNA fragmentomes. (2021)
• kataegis: an R package for identification and visualization of the genomic localized hypermutation regions using high-throughput sequencing. (2021)
• Macrophage Polarization States in the Tumor Microenvironment. (2021)
• Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. (2021)
• TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data. (2021)
• Polygenic risk scores: from research tools to clinical instruments. (2020)
• DNA mismatch repair promotes APOBEC3-mediated diffuse hypermutation in human cancers. (2020)
• Immuno-genomic landscape of osteosarcoma. (2020)
• Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. (2020)
• Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. (2020)
• The repertoire of mutational signatures in human cancer. (2020)
• Pan-cancer landscape of homologous recombination deficiency. (2020)
• Cancer PRSweb: An Online Repository with Polygenic Risk Scores for Major Cancer Traits and Their Evaluation in Two Independent Biobanks. (2020)
• Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers. (2020)
• AmpliconReconstructor integrates NGS and optical mapping to resolve the complex structures of focal amplifications. (2020)
• Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors. (2020)
• Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. (2020)
• Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. (2020)
• Super-enhancers: critical roles and therapeutic targets in hematologic malignancies. (2019)
• Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. (2019)
• Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. (2019)
• The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment. (2019)
• Genome-Informed Targeted Therapy for Osteosarcoma. (2019)
• Genome-wide cell-free DNA fragmentation in patients with cancer. (2019)
• Best practices for bioinformatic characterization of neoantigens for clinical utility. (2019)
• A Compendium of Mutational Signatures of Environmental Agents. (2019)
• Pan-cancer whole-genome analyses of metastatic solid tumours. (2019)
• Circular DNA elements of chromosomal origin are common in healthy human somatic tissue. (2018)
• The Cancer Spliceome: Reprograming of Alternative Splicing in Cancer. (2018)
• Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. (2018)
• Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. (2018)
• A fast detection of fusion genes from paired-end RNA-seq data. (2018)
• Quantification of subclonal selection in cancer from bulk sequencing data. (2018)
• Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. (2018)
• Enhanced detection of circulating tumor DNA by fragment size analysis. (2018)
• Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. (2018)
• Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes (2018)
• Molecular profiling and sequential somatic mutation shift in hypermutator tumours harbouring POLE mutations. (2018)
• EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. (2018)
• Patterns and mechanisms of structural variations in human cancer. (2018)
• Thymic involution and rising disease incidence with age. (2018)
• Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. (2017)
• OncoKB: A Precision Oncology Knowledge Base. (2017)
• Patient-derived xenografts undergo mouse-specific tumor evolution. (2017)
• Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors. (2017)
• Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. (2017)
• Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. (2017)
• A method to reduce ancestry related germline false positives in tumor only somatic variant calling. (2017)
• Comprehensive Analysis of Hypermutation in Human Cancer. (2017)
• Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. (2016)
• B lymphocytes and cancer: a love-hate relationship. (2016)
• Fragment Length of Circulating Tumor DNA. (2016)
• FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. (2016)
• Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. (2016)
• APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication. (2016)
• Development and clinical application of an integrative genomic approach to personalized cancer therapy. (2016)
• DGIdb 2.0: mining clinically relevant drug-gene interactions. (2016)
• Quantifying Clonal and Subclonal Passenger Mutations in Cancer Evolution. (2016)
• Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. (2015)
• BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. (2015)
• The landscape of long noncoding RNAs in the human transcriptome. (2015)
• A germline polymorphism of thymine DNA glycosylase induces genomic instability and cellular transformation. (2014)
• MBASED: allele-specific expression detection in cancer tissues and cell lines. (2014)
• Unraveling the clonal hierarchy of somatic genomic aberrations. (2014)
• Hidden Markov Model-Based CNV Detection Algorithms for Illumina Genotyping Microarrays. (2014)
• RADIA: RNA and DNA integrated analysis for somatic mutation detection. (2014)
• Genome-wide analysis of noncoding regulatory mutations in cancer. (2014)
• MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. (2014)
• CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. (2014)
• PVT1 dependence in cancer with MYC copy-number increase. (2014)
• Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'-UTR landscape across seven tumour types. (2014)
• An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. (2014)
• The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. (2014)
• PyClone: statistical inference of clonal population structure in cancer. (2014)
• DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. (2013)
• Cancer genome landscapes. (2013)
• Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data. (2013)
• Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. (2013)
• Ewing sarcoma protein: a key player in human cancer. (2013)
• Signatures of mutational processes in human cancer. (2013)
• A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. (2013)
• Mutational heterogeneity in cancer and the search for new cancer-associated genes. (2013)
• DGIdb: mining the druggable genome. (2013)
• Computational approaches to identify functional genetic variants in cancer genomes. (2013)
• Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. (2013)
• Absolute quantification of somatic DNA alterations in human cancer. (2012)
• High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. (2012)
• Myeloid cells in tumor inflammation. (2012)
• Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. (2012)
• Mutational processes molding the genomes of 21 breast cancers. (2012)
• Patient-derived tumour xenografts as models for oncology drug development. (2012)
• HLA typing from RNA-Seq sequence reads. (2012)
• Massive genomic rearrangement acquired in a single catastrophic event during cancer development. (2011)
• Outlier-Based Differential Expression Analysis in Proteomics Studies. (2011)
• Integrative analysis of the melanoma transcriptome. (2010)
• Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. (2005)

Merged raw entities (4)

All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.